Abobotulinumtoxina

CHEMBL2108570 Phase 4 Đã phê duyệt Unknown
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A purified protein derived from bacteria that temporarily paralyzes targeted muscles by blocking nerve signals that cause muscle contraction. It is used medically to treat conditions involving abnormal muscle stiffness or spasms, such as cervical dystonia and limb spasticity, as well as cosmetically to reduce facial wrinkles. Effects typically last three to four months, after which the treatment can be repeated.

Lĩnh vực điều trị

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

A purified protein derived from bacteria that temporarily paralyzes targeted muscles by blocking nerve signals that cause muscle contraction. It is used medically to treat conditions involving abnormal muscle stiffness or spasms, such as cervical dystonia and limb spasticity, as well as cosmetically to reduce facial wrinkles. Effects typically last three to four months, after which the treatment can be repeated.

Yes, Abobotulinumtoxina is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108570. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.